Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
March 28, 2022 16:05 ET
|
Cyclacel
-Initial Data from Phase 1/2 Study of Oral Fadraciclib in Solid Tumors Expected in First Half of 2022 – -Cash Runway to Mid 2023- -Conference Call Scheduled for March 28, 2022, at...
Cyclacel Pharmaceuticals to Participate in Biotech Showcase 2022 Virtual Conference
December 23, 2021 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Onconova Therapeutics Announces the Presentation of Preliminary Clinical Data Providing Evidence of Rigosertib’s Activity in RDEB-associated Squamous Cell Carcinoma
December 02, 2021 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Cyclacel Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Business Update
August 03, 2021 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann’s Virtual 2021 Healthcare Conference
July 07, 2021 07:15 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., July 07, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals to Present at Biotech Showcase™ Digital 2021
December 30, 2020 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel’s Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential in Esophageal Cancer and Acute Leukemia
December 01, 2016 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...